There are currently 2030 clinical trials in Chicago, Illinois looking for participants to engage in research studies. Trials are conducted at various facilities, including Northwestern University, Rush University Medical Center, University of Chicago and University of Chicago Comprehensive Cancer Center. Whether you're a healthy volunteer looking to participate in paid medical research or seeking trials related to a specific condition, the city provides a diverse range of opportunities near you.
Trial to Compare the Effects of Myo Munchee Therapy and Oral Motor Therapy (OMT) in Pediatric Patients to Treat Maxillary Deficiency and Orofacial Myofunctional Dysfunction (OMD).
NCT07088055
Recruiting
Multi-center, 6-month, randomized, and controlled trial to compare the effects of Myo Munchee therapy and Oral Motor Therapy (OMT) in pediatric patients (aged 3-5 years) to treat maxillary deficiency and orofacial myofunctional dysfunction (OMD).
Gender:
ALL
Ages:
Between 3 years and 5 years
Trial Updated:
07/19/2025
Locations: Center for Svedhyaya Therapy Services, Chicago, Illinois +1 locations
Conditions: Orofacial Myofunctional Disorders, Myo Munchee, Oral Motor Therapy, Maxillary Deficiency
Register for Updates
Optimization of a mHealth Physical Activity Promotion Intervention With Mindful Awareness for AYAO (OPT2MOVE)
NCT05375162
Recruiting
The purpose of the present study is to utilize Multiphase Optimization Strategy (MOST)1 to test four social support and mindfulness components (e-coaching, buddy, general mindfulness training, and MVPA-specific mindfulness training) in a 12-week mHealth moderate to vigorous intensity physical activity (MVPA) intervention in a sample of young adult cancer survivors (YACS), to improve quality of life (QOL) and decrease adverse effects and symptom burden. PRIMARY AIM To identify which components f... Read More
Gender:
ALL
Ages:
Between 18 years and 39 years
Trial Updated:
07/18/2025
Locations: Northwestern University, Chicago, Illinois
Conditions: Cancer
Register for Updates
A Study to Learn if a Combination of Fianlimab and Cemiplimab Versus Cemiplimab Alone is More Effective for Adult Participants With Advanced Non-Small Cell Lung Cancer (NSCLC)
NCT05785767
Recruiting
This study is researching an experimental drug called fianlimab (also called REGN3767), combined with a medication called cemiplimab (also called REGN2810), individually called a "study drug" or collectively called "study drugs". The study is focused on patients who have advanced non-small cell lung cancer (NSCLC). The aim of the study is to see how effective the combination of fianlimab and cemiplimab is in treating advanced NSCLC, in comparison with cemiplimab by itself. The study is looking... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
07/18/2025
Locations: University of Illinois, Chicago, Illinois
Conditions: Advanced Non-Small Cell Lung Cancer
Register for Updates
An Efficacy and Safety Study of Intravenous Anifrolumab to Treat Systemic Lupus Erythematosus in Pediatric Participants
NCT05835310
Recruiting
A Study to evaluate the PK, PD, efficacy, and safety of Anifrolumab in children with moderate to severe active SLE
Gender:
ALL
Ages:
Between 5 years and 17 years
Trial Updated:
07/18/2025
Locations: Research Site, Chicago, Illinois +1 locations
Conditions: Systemic Lupus Erythematosus
Register for Updates
Examining the Effects of Intra-detrusor Botox at Time of HoLEP in Men With Overactive Bladder Symptoms
NCT05878951
Recruiting
The objective of our multi-center randomized single-blind study is to examine the safety and effect of intra-detrusor OnabotulinumtoxinA injections at the time of holium laser enucleation of the prostate (HoLEP) in men with overactive bladder symptoms with and without urge incontinence.
Gender:
MALE
Ages:
Between 18 years and 89 years
Trial Updated:
07/18/2025
Locations: Northwestern Medicine, Chicago, Illinois
Conditions: Urinary Incontinence, Overactive Bladder Syndrome, Overactive Bladder, Urologic Diseases
Register for Updates
Nectero EAST System Clinical Study
NCT06001918
Recruiting
The purpose of this randomized clinical trial is to treat patients with small to mid-sized abdominal aortic aneurysms (AAA), maximum diameter of 3.5 cm to 5.0 cm, using a locally delivered, single-dose endovascular treatment. The main question the study aims to answer is to demonstrate efficacy of the product for stabilization of these small to mid-sized AAA.The study will compare the treatment group to the typical standard of care for these patients, surveillance. All subjects will be followed... Read More
Gender:
ALL
Ages:
Between 21 years and 85 years
Trial Updated:
07/18/2025
Locations: University of Chicago, Chicago, Illinois
Conditions: Abdominal Aortic Aneurysm
Register for Updates
A US Study to Evaluate Transarterial Radioembolization (TARE) in Combination With Durvalumab and Bevacizumab Therapy in People With Unresectable Hepatocellular Carcinoma Amenable to TARE
NCT06040099
Recruiting
The purpose of this study is to measure the efficacy and safety of durvalumab intravenous (IV) solution plus bevacizumab IV solution after transarterial radioembolization (Yttrium 90 glass microspheres TARE) in participants with unresectable hepatocellular carcinoma (HCC) amenable to embolization.
Gender:
ALL
Ages:
Between 18 years and 130 years
Trial Updated:
07/18/2025
Locations: Research Site, Chicago, Illinois
Conditions: Hepatocellular Carcinoma (HCC)
Register for Updates
Brain-Based and Clinical Phenotyping of Pain Pharmacotherapy in Knee Osteoarthritis
NCT06245109
Recruiting
This is a clinical trial of people who have pain due to knee osteoarthritis at Northwestern University Feinberg School of Medicine. The study will last for about 20 weeks. 180 qualified participants will be randomly assigned in a 1:1:1 ratio (60 participants per group) to one of three treatment groups: duloxetine, celecoxib, or placebo. Participants will have an Xray, knee MRI, brain MRI, blood draws, pain sensitivity testing, and asked to fill out questionnaires. The purpose of this study is to... Read More
Gender:
ALL
Ages:
41 years and above
Trial Updated:
07/18/2025
Locations: Northwestern University, Chicago, Illinois
Conditions: Knee Osteoarthritis
Register for Updates
Ureteroscopy With High-powered Holmium:Yag Laser Lithotripsy With and Moses On or Moses Off
NCT06346483
Recruiting
The purpose of this study is to compare Moses 2.0 pulse modulation technology and the standard high powered Holmium Laser lithotripsy and how it will affect time in the operating room, time using the laser, laser energy, and stone free rates. Currently Moses 2.0 laser technology is FDA approved and currently used in practice since 2021. No study to this date has compared Moses 2.0 without pulse modulation laser technology to Moses 2.0 with pulse modulation laser technology. The study will be i... Read More
Gender:
ALL
Ages:
Between 18 years and 90 years
Trial Updated:
07/18/2025
Locations: Northwestern Medicine, Chicago, Illinois
Conditions: Kidney Stone, Ureteral Stone
Register for Updates
Avalus Ultra Post-Approval Study (PAS)
NCT06506903
Recruiting
The purpose of this study is to characterize the safety and effectiveness of the Medtronic Avalus Ultra aortic valve bioprosthesis in patients with aortic valve disease.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
07/18/2025
Locations: Northwestern Memorial Hospital, Chicago, Illinois
Conditions: Aortic Valve Disease
Register for Updates
A Clinical Study of Sacituzumab Tirumotecan (MK-2870) in Patients With Bladder Cancer (MK-2870-027)
NCT06637423
Recruiting
The goal of the study is to learn about the safety of Sacituzumab Tirumotecan and if people can tolerate it when given in the bladder and find the highest dose that people can take without having certain problems. Researchers will then choose a dose level of Sacituzumab Tirumotecan to use in future studies to learn how well the drug works.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
07/18/2025
Locations: Northwestern University ( Site 0051), Chicago, Illinois
Conditions: Non-Muscle Invasive Bladder Cancer
Register for Updates
A Study to Assess the Efficacy and Safety of Lorundrostat in Participants With Obstructive Sleep Apnea and Hypertension
NCT06785454
Recruiting
The primary purpose of the study is to assess the effect of lorundrostat taken orally (po) once a day on the Apnea-Hypopnea Index (AHI) in participants with moderate to severe obstructive sleep apnea (OSA) and hypertension.
Gender:
ALL
Ages:
Between 18 years and 75 years
Trial Updated:
07/18/2025
Locations: Chicago Research Center Inc, Chicago, Illinois
Conditions: Obstructive Sleep Apnea, Hypertension
Register for Updates